Compare NGNE & EBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | EBF |
|---|---|---|
| Founded | 2003 | 1909 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.2M | 519.5M |
| IPO Year | 2014 | 1994 |
| Metric | NGNE | EBF |
|---|---|---|
| Price | $35.40 | $21.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $63.57 | N/A |
| AVG Volume (30 Days) | ★ 219.9K | 160.6K |
| Earning Date | 05-08-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 4.85% |
| EPS Growth | 0.93 | ★ 7.79 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.08 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $16.30 |
| 52 Week High | $37.27 | $22.36 |
| Indicator | NGNE | EBF |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 56.43 |
| Support Level | $19.27 | $19.92 |
| Resistance Level | $36.37 | $22.36 |
| Average True Range (ATR) | 2.05 | 0.58 |
| MACD | 0.39 | 0.09 |
| Stochastic Oscillator | 95.22 | 75.39 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others. The company's single reportable segment : Print derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.